Psychedelic Therapy Shows Promise—but Who Truly Benefits?

Psychedelic-assisted therapy is gaining attention as a potential treatment for severe mental health conditions. Using substances like psilocybin and LSD within a controlled setting, this approach has shown promise for disorders such as treatment-resistant depression, anxiety, and addiction. However, experts stress that success depends on strict professional oversight and careful patient selection. A recent study led by Charité – Universitätsmedizin Berlin examined which patients benefit most from this emerging therapy. Researchers surveyed 158 therapists worldwide to identify key factors influencing outcomes. They found that individuals with stable social support, openness to new experiences, and secure relationships responded most positively.

The therapy works by deeply altering perception, emotions, and consciousness. This can encourage new neural pathways and increase mental flexibility. Yet, effects vary widely between patients, and not everyone is a suitable candidate. Therapists warn that certain personality traits may pose risks. Patients with paranoid, schizoid, or schizotypal tendencies, as well as those with narcissistic, antisocial, or borderline traits, require extra caution. The treatment is not a quick fix—it demands thorough preparation, guided sessions, and follow-up care to ensure safety and effectiveness. Due to its intensity, psychedelic-assisted therapy must only take place in specialised centres. The environment, professional supervision, and integration support are all critical to achieving lasting benefits.

While psychedelic-assisted therapy offers hope for conditions resistant to traditional treatments, its success hinges on careful patient selection and expert guidance. The Charité study highlights the importance of social stability and psychological readiness. Without proper safeguards, the therapy’s potential risks could outweigh its benefits.